|
Prevention of Osteoporosis in Men with Prostate Cancer Clinical Trials Info presented on Clinical Trials Search is not intended to be a substitute for certified medical advice, visits or professional assistance using a real physician. We are not physicians. Always consult your dr. about Prevention of Osteoporosis in Men with Prostate Cancer conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Prevention of Osteoporosis in Men with Prostate Cancer Clinical research trials and Prevention of Osteoporosis in Men with Prostate Cancer health trials happen in many of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new drugs. The function of the studies / projects is to resolve particular human medical questions. Clinical trials are a popular manner for mDs, government agencies, and private sector corporations to discover remedies for all varieties of circumstances, like Prevention of Osteoporosis in Men with Prostate Cancer. Prevention of Osteoporosis in Men with Prostate Cancer Clinical Trials and other clinical trials allow volunteers to obtain healthcare treatment options before they are available to the masses. Some times the participants undergo professional assistance for free of charge, and occasionally they are paid for their time. Sometimes there is a cost for a Prevention of Osteoporosis in Men with Prostate Cancer clinical trial. Human subjects often get the best healthcare available for their Prevention of Osteoporosis in Men with Prostate Cancer condition. Dangers are a reality, however, and may include additional or frequent mD visits, healthcare dangers (potentially life-jeopardising), and/or the treatment being ineffectual. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Prevention of Osteoporosis in Men with Prostate Cancer  Prevention of Osteoporosis in Men with Prostate Cancer
Prevention of Osteoporosis in Men with Prostate Cancer
For Condition: Hypogonadism,Osteoporosis,Prostate Cancer
Status: No longer recruiting
Sponsor(s): National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) ,
Synopsis: The purpose of this two year study is to examine the safety and effectiveness of alendronate (Fosamax) for the prevention of bone loss in men with prostate cancer who are on therapy to lower their testosterone levels. All men will receive appropriate calcium and vitamin D supplements and one to two years of alendronate therapy. Bone density tests will be done every six months.
Details: Prostate cancer is the most common visceral malignancy and second leading cause of cancer death in men. While androgen ablation therapy is the cornerstone of treatment for more advanced stage disease, recent studies suggest the advantage of introducing androgen deprivation much earlier. Because androgens are essential in maintaining skeletal integrity in men, androgen deprivation therapy constitutes a major risk factor for male osteoporosis. We have previously demonstrated that men on chronic androgen deprivation therapy have up to 20% loss of bone. Our hypotheses are that: 1) chronically increased bone resorption induced by long term androgen deprivation therapy in men with prostate cancer can be reversed with once weekly bisphosphonate; 2) the improvement in bone mass with bisphosphonate therapy will be reflected by changes in biochemical markers of bone turnover and will allow us to predict who will respond to therapy; and 3) following termination of bisphosphonate therapy, bone mass will be maintained despite the absence of antiresorptive therapy. To address these hypotheses, we will enroll 84 men with stage D0 prostate cancer who have been on chronic androgen deprivation therapy in a two year, double blind, placebo controlled, randomized, modified crossover clinical design. During the first year, subjects will be randomized to bisphosphonate therapy or placebo. During the second year, all subjects who were on placebo will receive active treatment and all subjects who were on active treatment will be randomly assigned to continue therapy or change to placebo. To evaluate the effect of bisphosphonate on preventing bone loss, we will assess bone mass of the spine, total hip, total body, and forearm by dual-energy X-ray absorptiometry. For hypothesis 2, we will assess markers of bone resorption and formation to determine if early changes in markers are associated with long term changes in bone mass. For hypothesis 3, we will continue to follow bone mass and biochemical markers of bone turnover between months 12 and 24 to examine rates of change when antiresorptive therapy is terminated. Few data are available on the prevention of bone loss in men on androgen deprivation therapy. This study will examine a preventive strategy, the potential mechanism of bone loss, the ability of biochemical markers to predict bone mass, and skeletal outcomes when antiresorptive therapy is withdrawn.
Eligibility:
Study Type: Interventional, Prevention, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 50 Years/85 Years
Genders: Male
Protocol Entry Criteria: Inclusion Criteria: - Men age 50-85 - Stage D0 prostate cancer - On androgen deprivation therapy Exclusion Criteria: - Renal failure - Hyperthyroidism - Cushing's syndrome - Metabolic bone disease - Use of glucocorticoids - Use of certain anticonvulsants - On osteoporosis therapies - Nonprostate cancers
Total Enrollment: 112
Location and Contact Information:
Overall Study Official:
SusanGreenspan, Principal Investigator, University of Pittsburgh
Osteoporosis Prevention & Treatment Center
Pittsburgh, Pennsylvania, 15213-3221
United States
Additional Information:
Study ID Numbers: DK61535;
Study Start Date: May 2002
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00048841
Other Hypogonadism Studies:
1. Follow-up study for men diagnosed with prostate cancer through participation in a prostate specific antigen screening program
2. PSA-Based Vaccine and Radiotherapy to Treat Localized Prostate Cancer
3. Selenium and Vitamin E in Preventing Prostate Cancer
4. Preoperative Thalidomide Followed By Radical Retropubic Prostatectomy In Select Patients With Locally Advanced Prostate Cancer
5. Single-Dose Local Radiation Therapy Compared With Ibandronate in Treating Patients With Localized Metastatic Bone Pain
Related Studies:
Other Hypogonadism Clinical Trials
Other Pennsylvania Clinical Trials
Other Pittsburgh Clinical Trials
Prevention of Osteoporosis in Men with Prostate Cancer
|
|
|
|
|
|
|
|
